Camp4 Therapeutics Corp 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held by Camp4 Therapeutics Corp on June 11, 2025. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Cambridge, MA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were approved at the Annual Meeting:
- Election of Class I Directors: All four nominees were elected to serve three-year terms until the 2028 annual meeting.
- James Boylan: 15,802,709 For; 900,961 Against; 6,002 Abstain.
- Amir Nashat, ScD: 16,050,167 For; 653,504 Against; 6,001 Abstain.
- Andrew J. Schwab: 16,050,167 For; 653,504 Against; 6,001 Abstain.
- Douglas Williams, PhD: 16,700,927 For; 2,744 Against; 6,001 Abstain.
- Ratification of Independent Auditor: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
- Votes: 17,900,199 For; 2,644 Against; 6,002 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirm the total number of shares entitled to vote versus the total votes cast to assess shareholder participation rates.
- Verify the specific terms of the three-year director mandates ending in 2028.
- Review the Definitive Proxy Statement filed on April 30, 2025, for detailed background on the director nominees and auditor selection.